Literature DB >> 12397047

The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease.

Ian H De Boer1, Irina Gorodetskaya, Belinda Young, Chi-Yuan Hsu, Glenn M Chertow.   

Abstract

Secondary hyperparathyroidism (SHPT) is an important complication of end-stage renal disease. However, SHPT begins during earlier stages of chronic renal insufficiency (CRI), and little is known about risk factors for SHPT in this population. This study evaluated 218 patients in an ethnically diverse ambulatory nephrology practice at the University of California San Francisco during calendar years 1999 and 2000. Demographic data, comorbid diseases, medications, and laboratory parameters were collected, and independent correlates of intact parathyroid hormone (PTH) were identified by using multiple linear regression. The mean estimated GFR was 34 ml/min per 1.73 m(2) (10%-90% range, 13 to 61 ml/min per 1.73 m(2)); PTH was inversely related to GFR (P < 0.0001). The adjusted mean PTH was higher among African Americans and lower among Asian/Pacific Islanders compared with white patients (233 versus 95 versus 139 pg/ml; P < 0.0001). Moreover, among the 196 patients with GFR <60 ml/min per 1.73 m(2), the slope of GFR versus PTH was significantly steeper among African Americans than among white patients (10.6 versus 3.9 pg/ml per ml per min per 1.73 m(2); P = 0.01). After adjusting for age and diabetes, PTH was associated with a history of myocardial infarction (OR, 1.6; 95% CI, 1.1 to 2.3 per unit natural log PTH) and congestive heart failure (OR, 2.0; 95% CI, 1.3 to 2.9 per unit natural log PTH) and not associated with other co-morbid conditions. These factors should be considered when screening and managing SHPT in CRI.

Entities:  

Mesh:

Year:  2002        PMID: 12397047     DOI: 10.1097/01.asn.0000034202.91413.eb

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  45 in total

Review 1.  Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

2.  Impact of Race on the Association of Mineral Metabolism With Heart Failure: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Cassianne Robinson-Cohen; Michael Shlipak; Mark Sarnak; Ronit Katz; Carmen Peralta; Bessie Young; Andrew N Hoofnagle; Moyses Szklo; Joachim H Ix; Bruce M Psaty; Ian H de Boer; Bryan Kestenbaum; Nisha Bansal
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

3.  Impact of activated vitamin D and race on survival among hemodialysis patients.

Authors:  Myles Wolf; Joseph Betancourt; Yuchiao Chang; Anand Shah; Ming Teng; Hector Tamez; Orlando Gutierrez; Carlos A Camargo; Michal Melamed; Keith Norris; Meir J Stampfer; Neil R Powe; Ravi Thadhani
Journal:  J Am Soc Nephrol       Date:  2008-04-09       Impact factor: 10.121

4.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

Review 5.  Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrology (Carlton)       Date:  2009-06       Impact factor: 2.506

6.  Risk factors for pseudogout in the general population.

Authors:  Young Hee Rho; Yanyan Zhu; Yuqing Zhang; Anthony M Reginato; Hyon K Choi
Journal:  Rheumatology (Oxford)       Date:  2012-08-11       Impact factor: 7.580

7.  A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

Authors:  Steven C Cheng; Daniel O Young; Yihung Huang; James A Delmez; Daniel W Coyne
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

8.  Mineral metabolites and CKD progression in African Americans.

Authors:  Julia J Scialla; Brad C Astor; Tamara Isakova; Huiliang Xie; Lawrence J Appel; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

9.  Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Authors:  Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed
Journal:  Am J Nephrol       Date:  2015-08-20       Impact factor: 3.754

10.  Cinacalcet treatment of primary hyperparathyroidism.

Authors:  H M Rothe; O Liangos; P Biggar; A Petermann; M Ketteler
Journal:  Int J Endocrinol       Date:  2011-03-06       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.